Standard Biotools (LAB) Preferred Stock Liabilities (2010 - 2023)
Standard Biotools (LAB) reported Preferred Stock Liabilities of $311.3 million for Q4 2023, little changed year-over-year from $311.3 million in Q4 2022, and little changed on a QoQ basis from $311.3 million in Q3 2023.
Standard Biotools (LAB) has 3 years of Preferred Stock Liabilities data on file, last reported at $311.3 million in Q4 2023.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $311.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $311.3 million (changed 0.0% YoY) and the FY2023 annual result came in at $311.3 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities steadied at $311.3 million in Q4 2023 per LAB's latest filing, from $311.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $311.3 million in Q2 2022 and bottomed at $311.3 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Standard Biotools | 448.37 Mn | -6.80 Mn | 11.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 311.25 Mn |
| Sep 30, 2023 | 311.25 Mn |
| Jun 30, 2023 | 311.25 Mn |
| Mar 31, 2023 | 311.25 Mn |
| Dec 31, 2022 | 311.25 Mn |
| Sep 30, 2022 | 311.25 Mn |
| Jun 30, 2022 | 311.25 Mn |
| Dec 31, 2010 | 184.55 Mn |